ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maintaining solid cash flow and margin, has a low-debt capital structure, and is fairly valued.
Resmed shares rise after Q2 EPS and revenues beat expectations, with the gross and operating margins expanding sharply across core segments.
ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Michael J. Farrell CEO | XHAN Exchange | US7611521078 ISIN |
| US Country | 9,980 Employees | 12 Feb 2026 Last Dividend | 31 Aug 2010 Last Split | 2 Jun 1995 IPO Date |
ResMed Inc. is a pioneering company focused on developing, manufacturing, distributing, and marketing medical devices alongside cloud-based software applications tailored for the healthcare markets. With its operational base divided between Sleep and Respiratory Care, and Software as a Service (SaaS), ResMed is at the forefront of offering innovative solutions for managing respiratory disorders. The company's extensive product lineup and software solutions cater to both medical and consumer needs, aiming to improve patient outcomes through advanced technology and connectivity. Founded in 1989 and headquartered in San Diego, California, ResMed markets its products globally through a combination of direct sales forces and a network of distributors, targeting sleep clinics, home healthcare dealers, and hospitals.